MDT-AP-3203
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 48.12
- os_event
- false
- age_years
- 29.62
- sex
- F
- new_clusters
- S1
- umap1_2d
- 0.20957215
- umap2_2d
- -11.26597029
- umap1_3d
- -3.742895203
- umap2_3d
- 0.164876866
- umap3_3d
- 6.431635162
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.360
- E2F_TARGETS+0.350
- MITOTIC_SPINDLE+0.310
- NOTCH_SIGNALING+0.260
- PROTEIN_SECRETION+0.220
- MYC_TARGETS_V1+0.150
- ANDROGEN_RESPONSE+0.140
- WNT_BETA_CATENIN_SIGNALING+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.100
- MTORC1_SIGNALING+0.090
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.420
- ANGIOGENESIS-0.370
- OXIDATIVE_PHOSPHORYLATION-0.370
- ALLOGRAFT_REJECTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.340
- KRAS_SIGNALING_UP-0.330
- ESTROGEN_RESPONSE_LATE-0.300
- MYOGENESIS-0.300
- COAGULATION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030942_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.849 |
| 2 | MDT-AP-1191 | Med | Medulloblastoma | 0.848 |
| 3 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.844 |
| 4 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.840 |
| 5 | TCGA-91-6847-01A-11R-1949-07 | — | cohortMD1 | 0.839 |
| 6 | MDT-AP-3325 | Med | Medulloblastoma | 0.836 |
| 7 | MDT-AP-0138 | Med | Medulloblastoma | 0.836 |
| 8 | BS_M0QYNVK8 | high-grade glioma | — | 0.834 |
| 9 | MDT-AP-0184 | Med | Medulloblastoma | 0.830 |
| 10 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.040 | Inavolisib | — uncovered |